Optimizing Recovery and Preservation of Endogenous Insulin Secretion in Individuals with Prediabetes or Recent Onset of Type 2 Diabetes (U01) | Apply Online

Opportunity Summary:

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), released this Funding Opportunity Announcement (FOA) to support clinical research focused on protecting and restoring the body is own insulin production in people with prediabetes or very early type 2 diabetes. The central idea is that beta cell dysfunction and loss of endogenous insulin secretion are key drivers of progression to worse hyperglycemia, and that there may be a meaningful window early in the disease course when beta cell function can be improved or preserved. Through this initiative, NIDDK is looking for well designed clinical studies that test practical strategies intended to recover insulin secretory capacity and then maintain those gains long enough to translate into better glucose control.

The FOA lays out two main scientific goals. First, it seeks studies that can determine whether short, intensive interventions can significantly improve both the pattern and the magnitude of endogenous insulin responses, clarify how much recovery is realistically achievable, and identify factors linked to recovery and longer term retention of insulin secretion. In practice, this means applicants are expected to measure beta cell function and insulin responses carefully before, during, and after the intervention, and then analyze which participant characteristics (for example baseline glycemia, weight, insulin resistance, duration of dysglycemia, or other clinical features) predict meaningful improvement. Second, the FOA emphasizes the need to determine how long any improvement lasts once the intervention ends, and whether that durability makes it easier for individuals to reach and sustain better glucose control. The program is not only interested in immediate physiologic changes, but also in whether those changes persist and matter clinically.

A notable optional component is biomarker discovery and validation. Applicants may propose efforts to identify biomarkers that could simplify beta cell function assessment and improve the ability to predict who will respond to a given intervention. This reflects a practical concern: gold standard physiologic testing can be intensive and expensive, so NIDDK is open to studies that can point to easier markers (blood based, imaging based, or other measurable indicators) that track beta cell recovery or forecast response. While not mandatory, this element can strengthen an application when it is well integrated with the clinical study design and endpoints.

The funding mechanism is a U01 cooperative agreement, which signals that NIH expects substantial programmatic involvement beyond a typical investigator initiated grant. Each awardee can propose a unique protocol, but the FOA makes clear that collaboration across funded projects is required. Awardees are expected to work together to establish common definitions, measures, and procedures so that data can be compared across different study designs. In effect, NIDDK wanted a coordinated set of clinical studies that could be interpreted side by side rather than a collection of isolated trials, improving the overall value of the findings and helping the field converge on shared standards for evaluating beta cell function and insulin secretion outcomes.

From an administrative standpoint, the opportunity was posted November 24, 2010, with an original and current closing date of March 24, 2011, and an archive date of April 24, 2011. The estimated total funding level listed is $4,000,000, and the program falls under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). There is no cost sharing or matching requirement indicated, which generally reduces barriers for applicants and allows budgets to be driven by the scientific and operational needs of the clinical study.

Eligibility is broad and includes many organization types that can run clinical research, such as public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non 501(c)(3) organizations), small businesses, for profit organizations (including those other than small businesses), state and local governments (including counties, cities or townships, special districts), and tribal governments and organizations. The announcement also explicitly mentions additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, faith based or community based organizations, Hispanic serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, regional organizations, eligible federal agencies, and U.S. territories or possessions. This wide eligibility suggests NIDDK was aiming to attract a diverse set of clinical research teams and settings, potentially including community based sites, academic medical centers, and specialized research networks capable of recruiting and closely following people early in dysglycemia.

In summary, this FOA funded collaborative clinical studies designed to test whether early, intensive, and potentially time limited interventions can restore and preserve endogenous insulin secretion in prediabetes or recent onset type 2 diabetes, determine how durable those effects are, and evaluate whether they translate into improved glycemic outcomes. It also encourages work on biomarkers that could make beta cell assessment easier and help match the right intervention to the right patient. The cooperative agreement structure and the requirement for shared measures underline that NIDDK prioritized a coordinated research portfolio where results could be compared and combined to accelerate progress in understanding and slowing early type 2 diabetes progression.

Browse more business programs for Diabetes Research

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health

Next opportunity: NEI Genomic Research Grant on Integrative Data Analysis for Vision Research (R01)

Previous opportunity: NIH Basic Behavioral and Social Science Opportunity Network (OppNet) Short term Mentored Career Development Awards in the Basic Behavioral and Social Sciences for Mid career and Senior Investigators (K18)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DK 10 013

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DK 10 013) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 10 013", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.